Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc. is a biotechnology company specializing in the research and development of innovative therapies for cancer and rare diseases. Established in 2012 and headquartered in New Taipei, Taiwan, Senhwa emphasizes first-in-class drug development, focusing on novel compounds to address unmet medical needs in oncology and beyond. The company's primary research efforts center around two key drug candidates: CX-5461, a next-generation DNA damage response agent designed for multiple tumor types, and CX-4945, a protein kinase inhibitor initially developed for several cancers and explored for potential applications in viral diseases. Senhwa applies rigorous scientific methodologies, leveraging operational bases in both Taiwan and San Diego, to advance its pipeline through global clinical collaborations in regions including Australia and the United States. By targeting gene-mutated cancers—particularly those resistant to existing treatments—Senhwa aims to transform current therapeutic standards in the biotechnology and pharmaceutical sectors. The company’s commitment to precision medicine and continuous clinical development highlights its role as an innovative driver within the life sciences industry.